On Oct. 12 Rx.Health Cofounder Dr. Ashish Atreja joined other leading minds in healthcare and business as he spoke at the Third Annual Financial Times Digital Health Summit in New York. While Dr. Atreja’s panel discussion focused on the changing dynamics on the frontline of digital health, discussions at the summit explored the trends and opportunities, funding, innovation and approaches needed to drive forward the digital age of health.
The conference was attended by CEOs, Chief Medical Officers, CFOs, CTOs, CIOs, Heads of Healthcare, Directors of Innovation, Heads of Disruptive Innovation, as well as other senior executives who target the latest consumer and patient demands. The focus of the conference was centered on how all participants in our healthcare system, from patient to provider to regulator, can work together to ensure that technology is consistent and effective in meeting the modern demands of patients and health services.
As healthcare embraces a patient-centric focus, providers are empowering patients to take meaningful control over their treatment. Clinicians are now under pressure to demonstrate the value of personalized healthcare through customized solutions. With this new reality in focus, panelists at the conference discussed how multiple goals can be aligned between patients and providers to optimize digital engagement.
The Financial Times is a leading international daily newspaper with an emphasis on business and economic news. With an average daily readership of 2.2 million people worldwide, the Financial Times is widely considered the most important business read currently in circulation. The publication reaches 36 percent of most senior financial decision makers at the world’s largest financial institutions.
In advance of World Mental Health Day, Healthcare IT News recently reported on Rx.Health’s recent strategic partnership with leading cognitive digital therapeutic app provider BrainCheck. As a result of the partnership, BrainCheck’s products will now be fully integrated onto Rx.Health’s RxUniverse Digital Medicine Prescribing Platform, which enables physicians to prescribe evidence-based mobile apps, multi-media education, wearables, and customized care plans for various diseases, procedures and surgeries at the point of care.
Experts estimate that up to 40 percent of people with Alzheimer’s disease suffer from depression. Cognitive impairment and mental health conditions often go hand-in-glove, with depression leading to difficulty “thinking” and impaired cognition leading to depression. Because both cognitive and psychiatric conditions can lead to decreased quality of life, it is critical to assess cognitive function in all mental health patients.
“Through our partnership with Rx.Health, we are now able to reach thousands of patients and providers in healthcare systems around the world,” said Dr. Yael Katz, co-founder and CEO of BrainCheck. “This signals a substantial step toward delivering on our promise of making a cognitive health assessment a routine part of healthcare.”
BrainCheck was conceptualized and spun out of the Baylor College of Medicine, where co-founder Dr. David Eagleman pioneered the vision of empowering patients to take control of their cognitive health with intuitive, interactive assessments. Widely recognized as a visionary in the field of neuroscience for over 20 years, Dr. Eagleman is also a New York Times best-selling author, a TED speaker, and the creator and host of the Emmy-nominated PBS series “The Brain.”
“If you’ve got your toe in the water of Digital Medicine, you’re aware that the application of digital therapeutics to cognitive wellness is tremendous and absolutely necessary,” said Pavan Choksi, who heads corporate development at Rx.Health. “BrainCheck not only represents the gold standard in this space, but also shares a similar ethos with Rx.Health as a data-driven company born out of a top academic medical center.”
Read Healthcare IT News coverage here, and the full press release announcing this exciting partnership here.
Rx.Health CEO Ed Berde recently joined eHealth Radio Network host Eric Michaels to talk about Digital Medicine and the RxUniverse platform. Berde was excited to discuss the company’s rebrand, and explained how important the “Rx” symbol was to the company as we move into the future of patient care by prescribing Digital Medicine.
Berde also defined Digital Medicine for Michaels and the audience as all of the mobile health apps, wearables and digital therapeutics that have undergone clinical trials and studies to prove that they can improve patient health outcomes.
“Digital Medicine is so powerful because these apps have been clinically proven to improve health outcomes during those 1,000 hours they are not with the doctor,” Berde said.
Rx.Health continues to gain media attention as the company grows and works to establish the field of Digital Medicine. Check back on our website to stay up to date on Rx.Health, the prescribers of Digital Medicine.
Rx.Health CEO Ed Berde was recently featured on AMC’s “Newswatch,” where he spoke with the show’s host, Andrew Tropeano about Digital Medicine, Rx.Health and the RxUniverse platform.
Berde explained how physicians can prescribe Digital Medicine directly to their patient’s smartphone and the difference between mHealth apps and clinically proven Digital Medicine.
Certain apps on the RxUniverse platform are designed to improve quality of life for patients who are struggling with managing chronic conditions, while other apps help guide patients through surgery and ensure they are taking the necessary steps to prepare for a procedure and have a smooth recovery after.
Rx.Health was featured during a three-minute segment during “Newswatch’s” episode on Monday, Sept. 25.
There’s a growing movement across the country calling for people to put down their mobile devices to promote human connectivity. However, there is a lack of awareness that smartphones can help individuals deal with a prevalent condition that often precludes them from social interaction: depression.
A recent study led by top research institutions found that certain smartphone apps were effective in significantly reducing depressive symptoms in patients struggling with mental disorders. Researchers at Australia’s National Institute of Complementary Medicine, along with colleagues at Harvard Medical School, the University of Manchester and the Black Dog Institute, published their findings in a paper titled, “The efficacy of smartphone-based mental health interventions for depressive symptoms: a meta-analysis of randomized controlled trials.”
The study aggregated and analyzed 18 eligible randomized controlled trials of 22 smartphone apps. These apps were then implemented in tests involving more than 3,400 male and female participants between the ages of 18 and 59. Participants’ mental conditions ranged from minor to major depression, bipolar disorder, anxiety and insomnia. Treatment offered by the apps varied, with participants receiving daily emails encouraging prompt engagement, audio exercises, and the promotion of learnt techniques to deal with challenging situations.
Joseph Firth, the study’s lead author and a postdoctoral research fellow at NICM, wrote, “Combined with the rapid technological advances in this area, these devices may ultimately be capable of providing instantly accessible and highly effective treatments for depression, reducing the societal and economic burden of this condition worldwide.” Firth continues, “the increasing media promotion and accessibility of apps for mental health now presents a ‘duty of care’ issue towards ensuring that people have information and understanding of evidence-based digital treatments for depression.”
As smartphones have become ubiquitous, and as health systems consolidate, employing mobile health solutions may provide a method for treating underserved patient populations. The NICM-led study highlights the potential opportunity to provide affordable and highly accessible care to patients, as nearly half of the world’s population lives in countries with a physiatrist/patient ratio of 1 to 100,000.
While the debate will no doubt continue around time spent on screens, the counterargument has emerged that digital therapies can augment physical and mental well-being. However, there is no evidence to suggest that using apps alone can outperform standard psychological therapies or reduce the need for antidepressant medications.